The FDA has given the go-ahead to an antibiotic developed by Merck to treat urinary tract and abdominal infections.
The drug, Recarbrio, mixes a previously approved antibiotic and relebactam, a beta-lactamase inhibitor made by Merck.
Global health officials have been urging drugmakers and regulators around the world to help bring more updated antibiotics to market to fight the growing issue of drug-resistant bacterial infections.
Analysts expect relebactam alone to generate about $200 million in sales between 2020 and 2024.
Read the Reuters report.
